Fresenius Kabi launches Phenylephrine Hydrochloride Injection, USP in US

German pharma company Fresenius Kabi has launched the Phenylephrine Hydrochloride Injection, USP in the US, which is an alpha-1 adrenergic receptor agonist indicated for raising blood pressure in adults with clinically important hypotension caused mainly from vasodilation, in such settings as anesthesia or septic shock. Fresenius Kabi Phenylephrine Hydrochloride Injection, USP has been rolled out […] The post Fresenius Kabi launches Phenylephrine Hydrochloride Injection, USP in US appeared first on PharmaNewsDaily.com.

German pharma company Fresenius Kabi has launched the Phenylephrine Hydrochloride Injection, USP in the US, which is an alpha-1 adrenergic receptor agonist indicated for raising blood pressure in adults with clinically important hypotension caused mainly from vasodilation, in such settings as anesthesia or septic shock.

Fresenius Kabi Phenylephrine Hydrochloride Injection, USP has been rolled out as a 1 mL single-dose vial and as 5 mL and 10 mL pharmacy bulk packages. Fresenius Kabi says that all the Phenylephrine presentations supplied by it are free from preservatives.

John Ducker – president and CEO of Fresenius Kabi USA said: “Fresenius Kabi is pleased to expand our anesthesia and analgesia portfolio with these three presentations of Phenylephrine Hydrochloride Injection.

“Generic alternatives like these play a vital role in patient care and support efforts to make medicines more affordable and accessible.”

Fresenius Kabi Phenylephrine Hydrochloride Injection, USP

Fresenius Kabi Phenylephrine Hydrochloride Injection, USP. Photo courtesy of Business Wire.

Fresenius Kabi is a global health care company which has specialization in medicines and technologies for infusion, transfusion and also clinical nutrition. The German pharma company is a developer, manufacturer and provider of injected and infused medicines in the US with particular expertise in producing generic alternatives to brand-name drugs.

For more pharma industry news, keep following Pharma News Daily.

The post Fresenius Kabi launches Phenylephrine Hydrochloride Injection, USP in US appeared first on PharmaNewsDaily.com.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

Total
0
Shares
Related Posts
Read More

NKMax America launches SNK01-MX03 clinical trial in plaque psoriasis

SNK01-MX03 clinical trial : NKMax America, a US biotech company, has initiated a phase 1 trial called SNK01-MX03 to investigate its ex vivo expanded autologous natural killer cell therapeutic SNK in plaque psoriasis. In this connection, NKMax America treated the first patient in the SNK01-MX03 clinical trial, which is a single center, dose-escalation study for […]

The post NKMax America launches SNK01-MX03 clinical trial in plaque psoriasis appeared first on PharmaNewsDaily.com.

Read More

Boehringer Ingelheim, Inflammasome to advance new therapies for retinal diseases

German pharma giant Boehringer Ingelheim has entered into a co-development and license agreement with US-based Inflammasome Therapeutics to develop new retinal disease therapies and reduce the patient burden for eye diseases. The company is planning to develop up to three therapies for patients with retinal diseases by integrating its retinal disease pipeline portfolio compounds with […]

The post Boehringer Ingelheim, Inflammasome to advance new therapies for retinal diseases appeared first on PharmaNewsDaily.com.